Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.
Yoshizaki
K
K
Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Japan.
Nishimoto
N
N
Mihara
M
M
Kishimoto
T
T
D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000918:Antibody Specificity; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D002417:Cattle; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology*; D008252:Macaca fascicularis; D051379:Mice; D008811:Mice, Inbred DBA; D051381:Rats; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins